Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $131.40 and last traded at $131.26, with a volume of 153 shares trading hands. The stock had previously closed at $131.25.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on ITCI. Needham & Company LLC reissued a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research report on Tuesday, March 4th. They set a "hold" rating for the company. Piper Sandler reiterated a "neutral" rating and issued a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Mizuho cut shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and cut their target price for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Finally, Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Ten research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $106.08.
View Our Latest Report on Intra-Cellular Therapies
Intra-Cellular Therapies Price Performance
The firm has a market cap of $13.96 billion, a P/E ratio of -150.91 and a beta of 0.69. The company's 50-day moving average is $120.15 and its two-hundred day moving average is $94.08.
Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.
Hedge Funds Weigh In On Intra-Cellular Therapies
Several hedge funds and other institutional investors have recently modified their holdings of ITCI. China Universal Asset Management Co. Ltd. boosted its stake in Intra-Cellular Therapies by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company's stock valued at $1,878,000 after buying an additional 2,157 shares in the last quarter. Barclays PLC lifted its holdings in shares of Intra-Cellular Therapies by 282.0% in the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock worth $2,521,000 after acquiring an additional 25,435 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Intra-Cellular Therapies by 31.9% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company's stock valued at $33,258,000 after purchasing an additional 109,892 shares in the last quarter. Oak Ridge Investments LLC grew its holdings in shares of Intra-Cellular Therapies by 74.1% during the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company's stock valued at $1,656,000 after purchasing an additional 8,440 shares during the last quarter. Finally, Cynosure Group LLC increased its position in Intra-Cellular Therapies by 161.0% during the 3rd quarter. Cynosure Group LLC now owns 14,442 shares of the biopharmaceutical company's stock worth $1,057,000 after purchasing an additional 8,909 shares in the last quarter. Institutional investors own 92.33% of the company's stock.
About Intra-Cellular Therapies
(
Get Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
